- Home
- SOR vs PEPG Comparison
SOR vs PEPG Comparison
Compare SOR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- PEPG
- Stock Information
- Founded
- SOR 1968
- PEPG 2018
- Country
- SOR United States
- PEPG United States
- Employees
- SOR N/A
- PEPG N/A
- Industry
- SOR Investment Managers
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- PEPG Health Care
- Exchange
- SOR Nasdaq
- PEPG Nasdaq
- Market Cap
- SOR 368.0M
- PEPG 317.6M
- IPO Year
- SOR N/A
- PEPG 2022
- Fundamental
- Price
- SOR $46.99
- PEPG $6.04
- Analyst Decision
- SOR
- PEPG Strong Buy
- Analyst Count
- SOR 0
- PEPG 6
- Target Price
- SOR N/A
- PEPG $9.50
- AVG Volume (30 Days)
- SOR 16.2K
- PEPG 748.2K
- Earning Date
- SOR 01-01-0001
- PEPG 11-12-2025
- Dividend Yield
- SOR 7.24%
- PEPG N/A
- EPS Growth
- SOR N/A
- PEPG N/A
- EPS
- SOR 6.50
- PEPG N/A
- Revenue
- SOR N/A
- PEPG N/A
- Revenue This Year
- SOR N/A
- PEPG N/A
- Revenue Next Year
- SOR N/A
- PEPG N/A
- P/E Ratio
- SOR $6.41
- PEPG N/A
- Revenue Growth
- SOR N/A
- PEPG N/A
- 52 Week Low
- SOR $36.41
- PEPG $0.88
- 52 Week High
- SOR $42.75
- PEPG $6.85
- Technical
- Relative Strength Index (RSI)
- SOR 66.23
- PEPG 63.91
- Support Level
- SOR $45.30
- PEPG $5.04
- Resistance Level
- SOR $47.39
- PEPG $5.97
- Average True Range (ATR)
- SOR 0.83
- PEPG 0.57
- MACD
- SOR 0.14
- PEPG 0.08
- Stochastic Oscillator
- SOR 83.69
- PEPG 95.22
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.